Trial Profile
MEDI4736 combinations in metastatic renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Savolitinib (Primary) ; Tremelimumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CALYPSO
- 24 Oct 2023 Results of updated 24-month efficacy analysis presented at the 48th European Society for Medical Oncology Congress.
- 18 Feb 2023 Results assessing relationship between MET, PD-L1 and TMB in these tumors and the relevance of other biomarkers including PIK3CA, PTEN and KRAS presented at the 2023 Genitourinary Cancers Symposium
- 12 Feb 2023 Results (n=41) investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer , published in the Journal of Clinical Oncology